Jubilant Flame International, Ltd. was formed on September 29, 2009 under the name Liberty Vision, Inc. and initially offered web development and marketing services to clients. In December 2012 the company disposed of its subsidiary to a shareholder for a nominal sum and changed its name to Jiu Feng Investment Hong Kong, Inc. On January 27, 2013 it announced the change of its ticker symbol from LBYV to JFIL. A shift to the medical sector occurred on July 24, 2013, and on August 18, 2015 the company adopted its current name, Jubilant Flame International, Ltd. From the fourth quarter of the fiscal year ended February 28, 2018 it began marketing and selling the imported Acropass Series cosmetics line in the United States, but it discontinued those activities at the start of 2020. Beginning in the third quarter of the year ended February 29, 2020 the firm commenced providing technical support services for the development of new nutrition food products intended for sale to customers in the USA. The company has not reported any significant revenue from either its former cosmetic operations or its current technical support services.

Jubilant Flame International, Ltd. presently reports zero sales revenue. The firm previously derived income from the sale of Acropass Series cosmetics in the United States until it halted that line in early 2020, although the filing does not specify the amount of revenue generated from that activity. Since the third quarter of the fiscal year ended February 29, 2020 the company has offered technical support services for nutrition food product development, and it has explicitly stated that no significant revenue has been derived from this service line. For the three months ended November 30, 2025 the company recorded a net loss of $14,496, compared with a net loss of $14,130 for the same period in 2024. For the nine months ended November 30, 2025 the net loss amounted to $46,998, up from $46,370 in the comparable period of 2024. Operating expenses during the three month period consisted of professional fees of $9,474, office expenses of $1,122 and OTC service and other charges of $3,900, totaling $14,496. For the nine month period operating expenses were $34,176 in professional fees, $1,122 in office expenses and $11,700 in OTC service and other, for a total of $46,998. The increase in expenses year over year was driven primarily by higher professional fee and OTC service costs. The company has not generated any cash from investing activities during these periods, and cash used in operating activities decreased from $53,275 in the nine months ended November 30, 2024 to $22,858 in the nine months ended November 30, 2025.

Jubilant Flame International, Ltd. operates within the medical and nutrition sectors, concentrating on technical support services for the development of new nutrition food products. Prior to 2020 the company participated in the United States cosmetics market through the sale of Acropass Series products, but it has since withdrawn from that line of business. The firm’s current operations generate no revenue and have resulted in an accumulated deficit of $3,892,614 as of November 30, 2025. As of that date the company reported current assets of $4,175 against current liabilities of $1,407,758, yielding a working capital deficit of $1,403,583. This financial situation raises substantial doubt about the company’s ability to continue as a going concern, and management indicates that additional financing will be required to sustain operations. The company plans to seek further capital through equity offerings, debt issuances or borrowings from financial institutions or related parties to support its business plan in the nutrition product technology support sector.

The company’s customers are located in the United States. Its technical support services are directed toward firms that intend to formulate and sell new nutrition items in the US market. Prior to 2020 the company’s cosmetic operations served US consumers who purchased imported Acropass Series products. No specific customer names are disclosed in the filing.